A higher restenosis rate of benign endobronchial mass after cryotherapy in endobronchial tuberculosis

Fu Tsai Chung, Hao Cheng Chen, Chun Liang Chou

Research output: Contribution to journalArticle

Abstract

Management of benign endobronchial mass with central airway obstruction remains challenging. The benefits and outcomes of cryotherapy in benign diseases are not clear, especially endobronchial tuberculosis. We collected medical records of patients with benign endobronchial mass who received cryotherapy and refused surgery as the first choice of treatment. Between 2007 and 2011,16 patients were included. The leading diagnosis was endobronchial tuberculosis (n = 9, 56.25%), followed by non-tuberculosis granuloma (n = 2, 12.5%), leiomyoma (n = 2, 12.5%), foreign body (n = 2, 12.5%), and chondroma (n = 1, 6.25%). The overall incidence of endobronchial lesion re-stenosis post-cryotherapy was 31.25% (5/16 patients). Patients with endobronchial tuberculosis had a higher re-stenosis rate, necessitating management, than patients with other diagnoses (56.25% vs. 0%; p value, 0.0174). The median follow-up duration of the patients was 15.25 months (n = 16; interquartile range, 7-36.13 months). The cumulative re-stenosis rate of endobronchial lesions was also higher in patients with endobronchial tuberculosis (80%; median duration, 17 months; p value, 0.036). Cryotherapy is feasible for the management of benign endobronchial mass. Among patients with endobronchial tuberculosis after cryotherapy removal, completed anti-tuberculosis treatment and regular follow-up are mandatory for higher restenosis rate. However, surgical treatment provides a rescue therapy among these patients when restenosis.

Original languageEnglish
Pages (from-to)99-106
Number of pages8
JournalJournal of Internal Medicine of Taiwan
Volume26
Issue number2
Publication statusPublished - Jan 1 2015
Externally publishedYes

Fingerprint

Cryotherapy
Tuberculosis
Pathologic Constriction
Chondroma
Leiomyoma
Airway Obstruction
Therapeutics
Foreign Bodies
Granuloma
Medical Records
Incidence

Keywords

  • Benign endobronchial mass
  • Cryotherapy
  • Endobronchial tuberculosis
  • Relapse rate

ASJC Scopus subject areas

  • Internal Medicine

Cite this

A higher restenosis rate of benign endobronchial mass after cryotherapy in endobronchial tuberculosis. / Chung, Fu Tsai; Chen, Hao Cheng; Chou, Chun Liang.

In: Journal of Internal Medicine of Taiwan, Vol. 26, No. 2, 01.01.2015, p. 99-106.

Research output: Contribution to journalArticle

@article{a81b0e53a1964498835209deb080a7a4,
title = "A higher restenosis rate of benign endobronchial mass after cryotherapy in endobronchial tuberculosis",
abstract = "Management of benign endobronchial mass with central airway obstruction remains challenging. The benefits and outcomes of cryotherapy in benign diseases are not clear, especially endobronchial tuberculosis. We collected medical records of patients with benign endobronchial mass who received cryotherapy and refused surgery as the first choice of treatment. Between 2007 and 2011,16 patients were included. The leading diagnosis was endobronchial tuberculosis (n = 9, 56.25{\%}), followed by non-tuberculosis granuloma (n = 2, 12.5{\%}), leiomyoma (n = 2, 12.5{\%}), foreign body (n = 2, 12.5{\%}), and chondroma (n = 1, 6.25{\%}). The overall incidence of endobronchial lesion re-stenosis post-cryotherapy was 31.25{\%} (5/16 patients). Patients with endobronchial tuberculosis had a higher re-stenosis rate, necessitating management, than patients with other diagnoses (56.25{\%} vs. 0{\%}; p value, 0.0174). The median follow-up duration of the patients was 15.25 months (n = 16; interquartile range, 7-36.13 months). The cumulative re-stenosis rate of endobronchial lesions was also higher in patients with endobronchial tuberculosis (80{\%}; median duration, 17 months; p value, 0.036). Cryotherapy is feasible for the management of benign endobronchial mass. Among patients with endobronchial tuberculosis after cryotherapy removal, completed anti-tuberculosis treatment and regular follow-up are mandatory for higher restenosis rate. However, surgical treatment provides a rescue therapy among these patients when restenosis.",
keywords = "Benign endobronchial mass, Cryotherapy, Endobronchial tuberculosis, Relapse rate, Benign endobronchial mass, Cryotherapy, Endobronchial tuberculosis, Relapse rate",
author = "Chung, {Fu Tsai} and Chen, {Hao Cheng} and Chou, {Chun Liang}",
year = "2015",
month = "1",
day = "1",
language = "English",
volume = "26",
pages = "99--106",
journal = "Journal of Internal Medicine of Taiwan",
issn = "1016-7390",
publisher = "臺灣內科醫學會",
number = "2",

}

TY - JOUR

T1 - A higher restenosis rate of benign endobronchial mass after cryotherapy in endobronchial tuberculosis

AU - Chung, Fu Tsai

AU - Chen, Hao Cheng

AU - Chou, Chun Liang

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Management of benign endobronchial mass with central airway obstruction remains challenging. The benefits and outcomes of cryotherapy in benign diseases are not clear, especially endobronchial tuberculosis. We collected medical records of patients with benign endobronchial mass who received cryotherapy and refused surgery as the first choice of treatment. Between 2007 and 2011,16 patients were included. The leading diagnosis was endobronchial tuberculosis (n = 9, 56.25%), followed by non-tuberculosis granuloma (n = 2, 12.5%), leiomyoma (n = 2, 12.5%), foreign body (n = 2, 12.5%), and chondroma (n = 1, 6.25%). The overall incidence of endobronchial lesion re-stenosis post-cryotherapy was 31.25% (5/16 patients). Patients with endobronchial tuberculosis had a higher re-stenosis rate, necessitating management, than patients with other diagnoses (56.25% vs. 0%; p value, 0.0174). The median follow-up duration of the patients was 15.25 months (n = 16; interquartile range, 7-36.13 months). The cumulative re-stenosis rate of endobronchial lesions was also higher in patients with endobronchial tuberculosis (80%; median duration, 17 months; p value, 0.036). Cryotherapy is feasible for the management of benign endobronchial mass. Among patients with endobronchial tuberculosis after cryotherapy removal, completed anti-tuberculosis treatment and regular follow-up are mandatory for higher restenosis rate. However, surgical treatment provides a rescue therapy among these patients when restenosis.

AB - Management of benign endobronchial mass with central airway obstruction remains challenging. The benefits and outcomes of cryotherapy in benign diseases are not clear, especially endobronchial tuberculosis. We collected medical records of patients with benign endobronchial mass who received cryotherapy and refused surgery as the first choice of treatment. Between 2007 and 2011,16 patients were included. The leading diagnosis was endobronchial tuberculosis (n = 9, 56.25%), followed by non-tuberculosis granuloma (n = 2, 12.5%), leiomyoma (n = 2, 12.5%), foreign body (n = 2, 12.5%), and chondroma (n = 1, 6.25%). The overall incidence of endobronchial lesion re-stenosis post-cryotherapy was 31.25% (5/16 patients). Patients with endobronchial tuberculosis had a higher re-stenosis rate, necessitating management, than patients with other diagnoses (56.25% vs. 0%; p value, 0.0174). The median follow-up duration of the patients was 15.25 months (n = 16; interquartile range, 7-36.13 months). The cumulative re-stenosis rate of endobronchial lesions was also higher in patients with endobronchial tuberculosis (80%; median duration, 17 months; p value, 0.036). Cryotherapy is feasible for the management of benign endobronchial mass. Among patients with endobronchial tuberculosis after cryotherapy removal, completed anti-tuberculosis treatment and regular follow-up are mandatory for higher restenosis rate. However, surgical treatment provides a rescue therapy among these patients when restenosis.

KW - Benign endobronchial mass

KW - Cryotherapy

KW - Endobronchial tuberculosis

KW - Relapse rate

KW - Benign endobronchial mass

KW - Cryotherapy

KW - Endobronchial tuberculosis

KW - Relapse rate

UR - http://www.scopus.com/inward/record.url?scp=84931081311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931081311&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84931081311

VL - 26

SP - 99

EP - 106

JO - Journal of Internal Medicine of Taiwan

JF - Journal of Internal Medicine of Taiwan

SN - 1016-7390

IS - 2

ER -